Your browser doesn't support javascript.
Systemic Cancer Therapy Does Not Significantly Impact Early Vaccine-Elicited SARS-CoV-2 Immunity in Patients with Solid Tumors.
Waickman, Adam T; Lu, Joseph; Chase, Corey; Fang, Hengsheng; McDowell, Erinn; Bingham, Erin; Bogart, Jeffrey; Graziano, Stephen; Thomas, Stephen J; Gentile, Teresa.
  • Waickman AT; Department of Microbiology and Immunology, State University of New York Upstate Medical University, Syracuse, NY 13210, USA.
  • Lu J; Institute for Global Health and Translational Sciences, State University of New York Upstate Medical University, Syracuse, NY 13210, USA.
  • Chase C; Department of Microbiology and Immunology, State University of New York Upstate Medical University, Syracuse, NY 13210, USA.
  • Fang H; Institute for Global Health and Translational Sciences, State University of New York Upstate Medical University, Syracuse, NY 13210, USA.
  • McDowell E; Department of Hematology and Oncology, State University of New York Upstate Medical University, Syracuse, NY 13210, USA.
  • Bingham E; Department of Microbiology and Immunology, State University of New York Upstate Medical University, Syracuse, NY 13210, USA.
  • Bogart J; Institute for Global Health and Translational Sciences, State University of New York Upstate Medical University, Syracuse, NY 13210, USA.
  • Graziano S; Department of Hematology and Oncology, State University of New York Upstate Medical University, Syracuse, NY 13210, USA.
  • Thomas SJ; Department of Hematology and Oncology, State University of New York Upstate Medical University, Syracuse, NY 13210, USA.
  • Gentile T; Department of Medical Oncology, State University of New York Upstate Medical University, Syracuse, NY 13210, USA.
Vaccines (Basel) ; 10(5)2022 May 09.
Article in English | MEDLINE | ID: covidwho-1862946
ABSTRACT
mRNA vaccines have been shown to be safe and effective in individuals with cancer. It is unclear, however, if systemic anti-cancer therapy impacts the coordinated cellular and humoral immune responses elicited by SARS-CoV-2 mRNA vaccines. To fill this knowledge gap, we assessed SARS-CoV-2 mRNA vaccine-elicited immunity in a cohort of patients with advanced solid tumors either under observation or receiving systemic anti-cancer therapy. This analysis revealed that SARS-CoV-2 mRNA vaccine-elicited cellular and humoral immunity was not significantly different in individuals with cancer receiving systemic anti-cancer therapy relative to individuals under observation. Furthermore, even though some patients exhibited suboptimal antibody titers after vaccination, SARS-CoV-2 specific cellular immune responses were still detected. These data suggest that antibody titers offer an incomplete picture of vaccine-elicited SARS-CoV-2 immunity in cancer patients undergoing active systemic anti-cancer therapy, and that vaccine-elicited cellular immunity exists even in the absence of significant quantities of SARS-CoV-2 specific antibodies.
Keywords
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study Topics: Vaccines Language: English Year: 2022 Document Type: Article Affiliation country: Vaccines10050738

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study Topics: Vaccines Language: English Year: 2022 Document Type: Article Affiliation country: Vaccines10050738